可溶性尿激酶纤溶酶原激活物受体与常染色体显性多囊肾病肾功能下降
在649例常染色体显性多囊肾病(ADPKD)患者中评估基线suPAR水平与随访eGFR下降及终末期肾病(ESRD)的关系。suPAR与身高校正总肾脏体积独立相关,最高三分位组3年eGFR下降19.4%且68%进展至CKD 3期,suPAR>2.82 ng/ml者ESRD风险增加3.38倍。
要点
- 基线suPAR水平与ADPKD患者3年eGFR下降及ESRD风险独立相关。
- suPAR最高三分位组3年eGFR下降19.4%,68%进展至CKD 3期。
- suPAR>2.82 ng/ml者发生ESRD的风险增加3.38倍。
核心结论
- suPAR水平与ADPKD患者肾功能进行性下降及新发ESRD相关,可能有助于早期识别疾病进展高风险患者。
研究设计与样本
- 对649例ADPKD患者进行至少3年计划随访,重复测量身高校正总肾脏体积和肌酐衍生eGFR。
- 采用线性混合模型分析重复测量数据,Cox比例风险模型分析基线suPAR与随访eGFR或新发ESRD的关联。
主要发现
- suPAR中位水平为2.47 ng/ml,身高校正总肾脏体积中位数为778,平均eGFR为84 ml/min per 1.73 m2。
- suPAR水平与身高校正总肾脏体积相关(β=0.02;95%CI 0.01至0.03),独立于年龄、性别、种族、高血压和eGFR。
- suPAR最低三分位组(<2.18 ng/ml)3年eGFR下降6.8%,22%进展至CKD 3期;最高三分位组(suPAR>2.83 ng/ml)3年eGFR下降19.4%,68%进展至CKD 3期。
- suPAR水平>2.82 ng/ml者新发ESRD风险增加3.38倍。
临床怎么用
- 在ADPKD患者中可考虑检测suPAR水平以辅助早期识别肾功能进展高风险个体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Levels of soluble urokinase plasminogen activator receptor (suPAR), an inflammation marker, are strongly predictive of incident kidney disease. Patients with autosomal dominant polycystic kidney disease (ADPKD) experience progressive decline in renal function, but rates of decline and outcomes vary greatly. Whether suPAR levels are predictive of declining kidney function in patients with ADPKD is unknown. METHODS: We assessed suPAR levels in 649 patients with ADPKD who underwent scheduled follow-up for at least 3 years, with repeated measurements of height-adjusted total kidney volume and creatinine-derived eGFR. We used linear mixed models for repeated measures and Cox proportional hazards to characterize associations between baseline suPAR levels and follow-up eGFR or incident ESRD. RESULTS: The median suPAR level was 2.47 ng/ml and median height-adjusted total kidney volume was 778, whereas mean eGFR was 84 ml/min per 1.73 m2. suPAR levels were associated with height-adjusted total kidney volume (β=0.02; 95% confidence interval, 0.01 to 0.03), independent of age, sex, race, hypertension, and eGFR. Patients in the lowest suPAR tertile (<2.18 ng/ml) had a 6.8% decline in eGFR at 3 years and 22% developed CKD stage 3, whereas those in the highest tertile (suPAR>2.83 ng/ml) had a 19.4% decline in eGFR at 3 years and 68% developed CKD stage 3. suPAR levels >2.82 ng/ml had a 3.38-fold increase in the risk of incident ESRD. CONCLUSIONS: suPAR levels were associated with progressive decline in renal function and incident ESRD in patients with ADPKD, and may aid early identification of patients at high risk of disease progression.
引用
- Hayek SS, Landsittel DP, Wei C, et al. Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2019. PMID: 31171572. doi:10.1681/ASN.2018121227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。